LMI has been selected through the Business Operations, Optimization, and Modernization Blanket Purchase Agreement to help the Food and Drug Administration modernize its business operations.
Through this 5-year, $149 million BPA, LMI will work to align operations with strategic priorities and improve the effectiveness of FDA organizations.
“With over 15 years of history with the FDA, LMI is privileged to continue strengthening this strategic partnership through the BOOM BPA,” said Zaki Saleh, LMI’s senior vice president of the health and civilian market.
As part of the work, LMI will deliver a broad set of service areas to deliver tactical and strategic support of FDA’s near and long-term activities.
These task areas include strategic planning, new business model development, organizational change management, policy effectiveness studies, resource and risk modeling, program and project management support, performance management services, coaching and mentoring, and project transition services.
“We look forward to improving the utilization of resources, process, and systems for the FDA, ensuring the seamless integration of projects and missions, and ultimately delivering protection and promotion of public health,” Saleh said.
LMI will also provide its full range of digital transformation capabilities to ensure alignment with FDA’s strategic goals and objectives.
These capabilities include new and revised business models; structured and productive sharing of technical, functional, process knowledge and skills; increased effectiveness of FDA policies, validity of related methods, business processes, and systems; increased access to trained and equipped resources; and increased use of data-driven, risk- and evidence-based decision making for finding opportunities and measuring results.
Ultimately, LMI plans to provide measurable accountability and continuous improvement of the organizational structures, policies and processes that govern resource management.